Everest Medicines Secures China Approval for CARDAMYST Nasal Spray to Treat Acute PSVT Episodes

Everest Medicines has received approval from China's National Medical Products Administration (NMPA) for CARDAMYST (etripamil) nasal spray, a novel, rapid-acting calcium channel blocker for the self-administration treatment of acute paroxysmal supraventricular tachycardia (PSVT) episodes in adults. This marks the first out-of-hospital, patient-administered treatment option for acute PSVT episodes in China, with treatment effects observed as early as five minutes after administration.